Neoadjuvant treatment with lenvatinib and pembrolizumab in a BRAF V600E-mutated anaplastic thyroid cancer: a case report

Neoadjuvant treatment with lenvatinib and pembrolizumab in a BRAF V600E-mutated anaplastic thyroid cancer: a case report

BackgroundTyrosine kinase inhibitors (TKIs) and immunotherapy have been proposed for advanced metastatic anaplastic thyroid cancer (ATC). We report a case of BRAF V600E-mutated ATC in which lenvatinib (L) plus pembrolizumab (P) enabled neoadjuvant treatment.Case presentationA male patient aged 65 ye...

Full description

Bibliographic Details
Main Authors: Daniele Barbaro, Raffaella Forleo, Maria Antonietta Profilo, Paola Lapi, Carlotta Giani, Liborio Torregrossa, Elisabetta Macerola, Gabriele Materazzi
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-07-01
Series:Frontiers in Endocrinology
Subjects:
anaplastic thyroid cancer
lenvatinib
pembrolizumab
BRAF mutation V600
neoadjuvant
Online Access:https://www.frontiersin.org/articles/10.3389/fendo.2024.1389294/full

Internet

https://www.frontiersin.org/articles/10.3389/fendo.2024.1389294/full

Similar Items